Kamada Ltd. Ordinary Shares (KMDA)

About KMDA

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for p…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

462

Website

www.kamada.com/

Fundamentals

1-day range

$8.24$8.35

Market cap

$417.07M

P/E (trailing)

20.65

P/E (forward)

13.89

EPS (trailing)

$0.35

Dividend yield

3.53%

Beta

0.92

Avg. volume

78.5K

Ex-dividend date

August 27, 2026

Dividend pay date

September 17, 2026

Forecasts

4 analyst ratings

Kamada Ltd. Ordinary Shares Competitors

Chosen by industry and closest market cap.

• KMDA

  Kamada Ltd. Ordinary Shares

  $8.29

  ▲ 0.36%
  Market cap $417.07MP/E 20.65
  $6.5$9.35
• BNTC

  Benitec Biopharma Inc. Common Stock

  $12.51

  ▼ 1.30%
  Market cap $417.41MP/E —
  $9.85$16.76
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $413.45MP/E —
  $2.72$6.42
• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $398.42MP/E —
  $3.86$9.12
• PRTA

  Prothena Corporation plc Ordinary Shares

  $9.35

  ▲ 2.86%
  Market cap $436.10MP/E —
  $7.73$11.8
• SGMT

  Sagimet Biosciences Inc. Series A Common Stock

  $10.55

  ▼ 1.86%
  Market cap $441.53MP/E —
  $4.5$11.15
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $391.42MP/E 18.65
  $4.3$9.51

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est
  Benzinga · 8/12/2026
• Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate
  Benzinga · 8/12/2026
• Options Exercise Update At Kamada: Lilach Payorski Engages, Resulting In $0
  Benzinga · 8/6/2026
• Options Exercise Activity Initiated By Leon Recanati At Kamada Worth $0
  Benzinga · 8/6/2026
• Insider Decision Making Waves At Kamada: David Tsur Exercises Options, Realizing $0
  Benzinga · 8/6/2026
• Benjamin Dekel Decides To Exercise Options At Kamada Worth $0
  Benzinga · 8/6/2026
• Ishay Davidi Decides To Exercise Options At Kamada Worth $0
  Benzinga · 8/6/2026

• Asher-Topilsky Lilach · August 5, 2026 · Grant

  30.0K
• Goldwasser Karnit · August 5, 2026 · Grant

  30.0K
• Tsur David · August 5, 2026 · Grant

  30.0K
• Leon Recanati · August 5, 2026 · Grant

  30.0K
• Dekel Benjamin · August 5, 2026 · Grant

  30.0K
• Lilach Payorski · August 5, 2026 · Grant

  30.0K
• Botzer Uri · August 5, 2026 · Grant

  30.0K
• ITSHAYEK ASSAF · August 5, 2026 · Grant

  30.0K
• DAVIDI ISHAY · August 5, 2026 · Grant

  30.0K
• Tsur David · April 7, 2026 · Grant

  6.6K
• Gorelik Boris · April 7, 2026 · Disposition

  3.8K
• Gorelik Boris · April 7, 2026 · Grant

  3.8K
• Reshef Liron · April 7, 2026 · Disposition

  15.0K
• Reshef Liron · April 7, 2026 · Grant

  15.0K
• Reshef Liron · April 7, 2026 · Disposition

  10.0K